Therapy News and Research

RSS

Exploring testosterone's influence on cardiovascular, metabolic, reproductive, and mental health

For decades, testosterone has been recognized as the primary driver of male reproductive development and secondary sex characteristics.

1 Sep 2025

Why metformin could protect the brain by rewiring mitochondria

Metformin boosts human oligodendrocyte differentiation and myelination across stem-cell, organoid, and chimera models. The study links these effects to mitochondrial metabolic shifts, supporting its potential as a therapy for multiple sclerosis.

1 Sep 2025

How a Mediterranean diet helps women manage menopausal symptoms

A cross-sectional study of 149 postmenopausal women found that greater adherence to a modified Mediterranean diet was linked to lower odds of moderate to severe hot flashes and sexual symptoms. While psychological and physical domains showed no significant association, the results support further evaluation of diet as a non-hormonal strategy for menopausal care.

1 Sep 2025

Gait retraining reduces pain and slows knee damage in osteoarthritis

Nearly a quarter of people over the age of 40 experience painful osteoarthritis, making it a leading cause of disability in adults.

1 Sep 2025

$New hypothesis links internal fat biology to heart failure with preserved ejection fraction$

New hypothesis links internal fat biology to heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person's internal fat tissue, according to the Adipokine Hypothesis, a new way of understanding how fat may impact the heart.

1 Sep 2025

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.

1 Sep 2025

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of patients with myocardial infarction (MI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Adding aspirin increased the risk of cardiovascular events, death and major bleeding in high-risk patients with chronic coronary syndrome (CCS) who had prior stenting and were receiving long-term chronic oral anticoagulation (OAC), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Tailored risk-based treatment does not improve outcomes in atrial fibrillation

An individually tailored multidimensional risk-based treatment strategy was not associated with improvements in clinical outcomes compared with usual guideline-based care in patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Triglyceride levels substantially reduced with olezarsen compared to placebo

Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

ICD treatment does not lower death risk in patients with abnormal ECG after myocardial infarction

Prophylactic implantable cardioverter defibrillator therapy did not reduce mortality in patients with a prior myocardial infarction, persistent moderate left ventricular systolic dysfunction and abnormal ECG markers, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a 5-mmHg reduction in systolic blood pressure at Month 3 compared with placebo, a difference that did not reach statistical significance.

1 Sep 2025

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Vericiguat reduced the risk of cardiovascular mortality, heart failure (HF) hospitalizations and all-cause mortality across a broad range of patients with HF and reduced ejection fraction (HFrEF), according to a pooled analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when given on top of individually optimized lipid-lowering therapy, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

$Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction$

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of patients with MI and mildly reduced left ventricular ejection fraction (LVEF), according to an individual patient data meta-analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Scientists discover molecular brake that limits T cell attack on tumors

In a discovery that could expand the array of current cancer immunotherapy treatments, scientists at Harvard Medical School have identified a new molecular brake that hinders the ability of T cells to attack tumors.

1 Sep 2025

Therapy News and Research

Exploring testosterone's influence on cardiovascular, metabolic, reproductive, and mental health

Why metformin could protect the brain by rewiring mitochondria

How a Mediterranean diet helps women manage menopausal symptoms

Gait retraining reduces pain and slows knee damage in osteoarthritis

New hypothesis links internal fat biology to heart failure with preserved ejection fraction

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Tailored risk-based treatment does not improve outcomes in atrial fibrillation

Triglyceride levels substantially reduced with olezarsen compared to placebo

ICD treatment does not lower death risk in patients with abnormal ECG after myocardial infarction

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

Scientists discover molecular brake that limits T cell attack on tumors

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News